Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679985 · ClinicalTrials.gov registry record · Phase 2
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
A Phase 2 study of Hepatocellular Carcinoma, sponsored by Coherus Oncology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT06679985 is a Phase 2 study of Hepatocellular Carcinoma that is actively recruiting participants, run by Coherus Oncology. The registered enrollment target is 72 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06679985, a Phase 2 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Coherus Oncology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Toripalimab
- DRUG Casdozokitug
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- City of Hope - Duarte
- City of Hope at Irvine Lennar - Irvine
- Cancer & Blood Specialty Clinic - Lakewood
- USC Norris Comprehensive Cancer Center - Los Angeles
- Sarcoma Oncology Center - Santa Monica
Arizona
- Mayo Clinic - Scottsdale - Scottsdale
- University of Arizona - Cancer Center - Tucson
New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
- Montefiore Medical Center - The Bronx
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James) - Columbus
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Georgia
- The Winship Cancer Institute Emory University - Atlanta
Idaho
- Mountain States Tumor Institute at St. Luke's Regional Medical Center - Boise
Kansas
- University of Kansas Cancer Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06679985
The ClinicalTrials.gov registry entry for NCT06679985 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (72% lower). The listed sponsor is Coherus Oncology, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06679985 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT06679985 about?
NCT06679985 is a clinical study titled "A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma". The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
What is the current status of trial NCT06679985?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2024-12-20. Estimated completion is 2027-09.
What conditions does trial NCT06679985 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06679985?
The interventions under investigation include: Bevacizumab (DRUG), Toripalimab (DRUG), Casdozokitug (DRUG).
Who is sponsoring clinical trial NCT06679985?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679985 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.